PMID- 16920505
OWN - NLM
STAT- MEDLINE
DCOM- 20061227
LR  - 20060821
IS  - 0171-2985 (Print)
IS  - 0171-2985 (Linking)
VI  - 211
IP  - 6-8
DP  - 2006
TI  - Principles of dendritic cell-based immunotherapy in myeloid leukemia.
PG  - 663-76
AB  - Persistent presence of minimal residual disease in myeloid leukemia carries the 
      risk of a relapse of the disease. In the setting of allogeneic transplants, 
      leukemic cells have been proven to be susceptible to the action of 
      immunocompetent T cells. Thus, an immunotherapeutic approach might hold promise 
      in the attempt to eradicate or control residual leukemia cells. Dendritic cells 
      (DCs) are very potent stimulators of immune responses and these cells have been 
      widely used to target other types of malignancies. This review discusses the 
      function and the applicability of leukemia-derived DCs for active specific 
      immunotherapy in myeloid leukemia including possible pitfalls, and describes 
      options to optimize DC-based vaccines.
FAU - Westers, Theresia M
AU  - Westers TM
AD  - Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081 
      HV Amsterdam, The Netherlands. tm.westers@vumc.nl
FAU - Houtenbos, Ilse
AU  - Houtenbos I
FAU - van de Loosdrecht, Arjan A
AU  - van de Loosdrecht AA
FAU - Ossenkoppele, Gert J
AU  - Ossenkoppele GJ
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20060721
PL  - Netherlands
TA  - Immunobiology
JT  - Immunobiology
JID - 8002742
SB  - IM
MH  - Animals
MH  - Dendritic Cells/*immunology/*transplantation
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Leukemia, Myeloid/immunology/*therapy
RF  - 90
EDAT- 2006/08/22 09:00
MHDA- 2006/12/28 09:00
CRDT- 2006/08/22 09:00
PHST- 2006/08/22 09:00 [pubmed]
PHST- 2006/12/28 09:00 [medline]
PHST- 2006/08/22 09:00 [entrez]
AID - S0171-2985(06)00083-0 [pii]
AID - 10.1016/j.imbio.2006.06.003 [doi]
PST - ppublish
SO  - Immunobiology. 2006;211(6-8):663-76. doi: 10.1016/j.imbio.2006.06.003. Epub 2006 
      Jul 21.